MedTrace Logo

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

NCT02712372 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2017-01-06

No results posted yet for this study

Summary

This is a Phase I, first-in-human (FIH) study to assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of AZD4831 after single and multiple ascending doses in healthy male subjects

Conditions

Interventions

DRUG

AZD4831

AZD4831 1-50 mg/g oral suspension

DRUG

AZD4831 placebo

AZD4831 placebo oral suspension

Sponsors & Collaborators

Principal Investigators

  • Rainard Fuhr, Dr. med. · PAREXEL Early Phase Clinical Unit Berlin, On the premises of Klinikum Westend, Haus 31, Spandauer Damm 130, 14050 Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2016-10-31
Completion
2016-10-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02712372 on ClinicalTrials.gov